Second allogeneic hematopoietic SCT for relapsed ALL in children

Bone Marrow Transplantation

Volumn 47, Issue 10, 2012, Pages 1307-1311

  Kato, M ^a   Horikoshi, Y ^b   Okamoto, Y ^c   Takahashi, Y ^d   Hasegawa, D ^e   Koh, K ^a   Takita, J ^f   Inoue, M ^g   Kigasawa, H ^h   Ogawa, A ⁱ   Sasahara, Y ^j   Kawa, K ^g   Yabe, H ^k   Sakamaki, H ^l   Suzuki, R ^m   Kato, K ⁿ  

^a SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

^b SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

^c KAGOSHIMA UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e HYOGO COLLEGE OF MEDICINE   (Japan)

^f UNIVERSITY OF TOKYO   (Japan)

^g RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^h KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

ⁱ NIIGATA CANCER CENTER HOSPITAL   (Japan)

^j TOHOKU UNIVERSITY   (Japan)

^k TOKAI UNIVERSITY   (Japan)

^l TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^m NAGOYA UNIVERSITY   (Japan)

ⁿ JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

more..

Author keywords

ALL; Children; Relapse; Second transplantation

Indexed keywords

BUSULFAN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CHILD; CHILDHOOD LEUKEMIA; FEMALE; FOLLOW UP; HLA MATCHING; HUMAN; INFANT; LEUKEMIA RELAPSE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELOABLATIVE CONDITIONING; NONRELAPSE MORTALITY; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RETREATMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; UNRELATED DONORS; WHOLE BODY RADIATION;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; RETROSPECTIVE STUDIES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84867399702     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.29     Document Type: Article

References (13)

1. Arellano ML, Langston A, Winton E, Flowers CR, Waller EK. Treatment of relapsed acute leukemia after allogeneic transplantation: a single center experience. Biol Blood Marrow Transplant 2007; 13: 116-123.
2. Blau IW, Basara N, Bischoff M, Gunzelmann S, Romer E, Kirsten D et al. Second allogeneic hematopoietic stem cell transplantation as treatment for leukemia relapsing following a first transplant. Bone Marrow Transplant 2000; 25: 41-45.
3. Bosi A, Laszlo D, Labopin M, Reffeirs J, Michallet M, Gluckman E et al. Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2001; 19: 3675-3684.
4. Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ et al. Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplant 2004; 34: 721-727.
5. Falantes JF, Carrillo E, Marquez F, Carmona M, Espigado I. Role of second hematopoietic stem cell transplantation in relapsed or refractory hematologic malignancies. Transplant Proc 2010; 42: 3225-3227.
6. Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuk F et al. Second allogeneic stem cell transplantation in myeloid malignancies. Acta Haematol 2009; 122: 185-192.
7. Konuma T, Ooi J, Takahashi S, Tomonari A, Tsukada N, Kato S et al. Second myeloablative allogeneic stem cell transplantation (SCT) using cord blood for leukemia relapsed after initial allogeneic SCT. Leuk Res 2009; 33: 840-842.
8. Michallet M, Tanguy ML, Socie G, Thiebaut A, Belhabri A, Milpied N et al. Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM). Br J Haematol 2000; 108: 400-407.
9. Munoz A, Badell I, Olive T, Verdeguer A, Gomez P, Bureo E. Second allogeneic hematopoietic stem cell transplantation in hematologic malignancies in children: long-term results of a multicenter study of the Spanish Working Party for Bone Marrow Transplantation in Children (GETMON). Haematologica 2002; 87: 331-332.
10. Pawson R, Potter MN, Theocharous P, Lawler M, Garg M, Yin JA et al. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant. Br J Haematol 2001; 115: 622-629.
11. Baron F, Storb R, Storer BE, Maris MB, Niederwieser D, Shizuru JA et al. Factors associated with outcomes in allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning after failed myeloablative hematopoietic cell transplantation. J Clin Oncol 2006; 24: 4150-4157.
12. Hosing C, Saliba RM, Shahjahan M, Estey EH, Couriel D, Giralt S et al. Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia. Bone Marrow Transplant; 2005; 36: 157-162.
13. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.